RPRX vs RGLD

For growth investors, Royal Gold, Inc.

(RGLD) is the stronger pick with 44. 6% revenue growth year-over-year, versus 5. 1% for Royalty Pharma plc (RPRX). Royalty Pharma plc (RPRX) offers the better valuation at 27. 9x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Royalty Pharma plc (RPRX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Royalty Pharma plc (RPRX) is the cheapest at 27.

9x versus Royal Gold, Inc. at 34. 8x. On forward P/E, Royalty Pharma plc is actually cheaper at 10. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Royalty Pharma plc wins at 1. 45x versus Royal Gold, Inc. 's 2. 51x — a reasonable growth-adjusted valuation.

Over the past 5 years, Royal Gold, Inc.

(RGLD) delivered a total return of +100. 5%, compared to +32. 4% for Royalty Pharma plc (RPRX). Over 10 years, the gap is even starker: RGLD returned +337. 6% versus RPRX's +22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Royalty Pharma plc (RPRX) is the lower-risk stock at 0.

45β versus Royal Gold, Inc. 's 0. 63β — meaning RGLD is approximately 38% more volatile than RPRX relative to the S&P 500. On balance sheet safety, Royal Gold, Inc. (RGLD) carries a lower debt/equity ratio of 13% versus 92% for Royalty Pharma plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Royal Gold, Inc.

(RGLD) is pulling ahead at 44. 6% versus 5. 1% for Royalty Pharma plc (RPRX). On earnings-per-share growth, the picture is similar: Royal Gold, Inc. grew EPS 32. 5% year-over-year, compared to -5. 8% for Royalty Pharma plc. Over a 3-year CAGR, RGLD leads at 20. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Royal Gold, Inc.

(RGLD) is the more profitable company, earning 45. 2% net margin versus 32. 4% for Royalty Pharma plc — meaning it keeps 45. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RPRX leads at 65. 6% versus 64. 5% for RGLD. At the gross margin level — before operating expenses — RPRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Royalty Pharma plc (RPRX) is the more undervalued stock at a PEG of 1. 45x versus Royal Gold, Inc. 's 2. 51x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Royalty Pharma plc (RPRX) trades at 10. 3x forward P/E versus 19. 5x for Royal Gold, Inc. — 9. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RGLD: 31. 0% to $304. 80.

All stocks in this comparison pay dividends.

Royalty Pharma plc (RPRX) offers the highest yield at 1. 3%, versus 0. 7% for Royal Gold, Inc. (RGLD).

For long-horizon retirement investors, Royal Gold, Inc.

(RGLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), 0. 7% yield, +337. 6% 10Y return). Both have compounded well over 10 years (RGLD: +337. 6%, RPRX: +22. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RPRX (Healthcare) and RGLD (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RPRX is a mid-cap quality compounder stock; RGLD is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.